LCTX — Lineage Cell Therapeutics, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 876343 ·
Last close
$1.03
Market Cap
$260.49M
52W High
$2.09
52W Low
$0.91
ADV30
1,222,253
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,069,000 | 1,069,000 | -8,923,000 | 1,482,000 | 106,220,000 | 37,355,000 | 46,422,000 |
| Mar 2026 | 1,725,000 | 1,725,000 | -7,593,000 | -4,812,000 | 109,533,000 | 35,939,000 | 56,838,000 |
| Dec 2025 | 6,608,000 | 6,542,000 | -6,548,000 | 851,000 | 112,584,000 | 40,791,000 | 69,238,000 |
| Sep 2025 | 3,681,000 | 3,676,000 | -3,786,000 | -29,781,000 | 89,639,000 | 40,463,000 | 68,843,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,816,000
Investing CF
$-13,712,000
Financing CF
$32,240,000
CapEx
$-574,000
Dividends Paid
—
Buybacks
$-41,000
EPS Diluted TTM
$-0.28
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-470,328,000
Inventory
—
Receivables
$790,000
ST Investments
$13,474,000
EBIT TTM
$-26,850,000
Pretax Income TTM
$-37,385,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,083,000
EBITDA
$-26,111,000
Free Cash Flow
$-14,774,250
Enterprise Value
$205,788,544
Total Cash
$50,829,000
Total Debt
$2,299,000
Shares Out
252,907,464
Trailing EPS
$-0.19
Book Value
$0.24
ROE
-60.1%
ROA
-17.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,556,000 | -21,779,000 | -63,533,000 | 112,584,000 | 69,238,000 | 44,549,000 | -18,919,000 |
| Dec 2024 | 9,499,000 | -21,478,000 | -18,609,000 | 113,218,000 | 36,206,000 | 78,381,000 | -23,092,000 |
| Dec 2023 | 8,945,000 | -24,733,000 | -21,486,000 | 101,019,000 | 38,996,000 | 63,419,000 | -28,566,000 |
| Dec 2022 | 14,703,000 | -22,520,000 | -26,273,000 | 123,664,000 | 51,728,000 | 73,339,000 | 1,059,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.10
Max Pain — expiry 2026-10-16
max pain strike: $1.00 · spot: $0.99 · call oi: 1,955 · put oi: 2
Expected Move to 2026-10-16:
±$0.10
(10.10%) —
implied range
$0.89 –
$1.09
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STRO | SUTRO BIOPHARMA, INC. | $264.97M | $15.98 | — |
| PALI | PALISADE BIO, INC. | $252.69M | $1.45 | — |
| LXEO | Lexeo Therapeutics, Inc. | $271.57M | $3.31 | — |
| IVVD | Invivyd, Inc. | $275.30M | $0.93 | — |
| FATE | FATE THERAPEUTICS INC | $281.58M | $2.35 | — |
News headlines (Yahoo Finance, 1h cache)
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
2026-09-08 12:00 · Yahoo
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
2026-08-14 00:32 · Yahoo
Lineage Cell Therapeutics Q2 Earnings Call Highlights
2026-08-09 19:04 · Yahoo
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
2026-07-30 12:00 · Yahoo
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan
2026-07-14 07:02 · Yahoo
Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage
2026-06-18 16:20 · Yahoo
How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets
2026-06-04 13:12 · Yahoo
Lineage Cell Therapeutics Q1 Earnings Call Highlights
2026-05-15 23:10 · Yahoo
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...
2026-05-13 05:02 · Yahoo
3 Small Cap Stocks With Strong Revenue Growth And Low Debt
2026-09-16 00:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.